{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:21:43Z","timestamp":1784953303852,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-115371RB-I00"],"award-info":[{"award-number":["PID2020-115371RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cientificas","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Von Hippel-Lindau (VHL) is a rare inherited disease mainly characterized by the growth of tumours, predominantly hemangioblastomas (Hbs) in the CNS and retina, and renal carcinomas. The natural history of VHL disease is variable, differing in the age of onset and its penetrance, even among relatives. Unfortunately, sometimes VHL shows more severe than average: the onset starts in adolescence, and surgeries are required almost every year. In these cases, the factor that triggers the appearance and growth of Hbs usually remains unknown, although additional mutations are suspected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We present the case of a VHL patient whose first surgery was at 13 years of age. Then, along his next 8 years, he has undergone 5 surgeries for resection of 10 CNS Hbs. To clarify this severe VHL condition, DNA from a CNS Hb and white blood cells (WBC) was sequenced using next-generation sequencing technology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Massive DNA sequencing of the WBC (germ line) revealed a pathogenic mutation in <jats:italic>CHEK2<\/jats:italic> and the complete loss of a <jats:italic>VHL<\/jats:italic> allele (both tumour suppressors). Moreover, in the tumour sample, several mutations, in <jats:italic>BRAF1<\/jats:italic> and <jats:italic>PTPN11<\/jats:italic> were found. Familiar segregation studies showed that <jats:italic>CHEK2<\/jats:italic> mutation was in the maternal lineage, while <jats:italic>VHL<\/jats:italic> was inherited by paternal lineage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Finally, clinical history correlated to the different genotypes in the family, concluding that the severity of these VHL manifestations are due to both, <jats:italic>VHL<\/jats:italic>-and-<jats:italic>CHEK2<\/jats:italic> mutations. This case report aims to notice the importance of deeper genetic analyses, in inherited rare diseases, to uncover non-expected mutations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00701-023-05825-x","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:01:54Z","timestamp":1697443314000},"page":"4241-4251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mutation in Chek2 triggers von Hippel-Lindau hemangioblastoma growth"],"prefix":"10.1007","volume":"165","author":[{"given":"Jorge","family":"Cabrera-Montes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Vi\u00f1as-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lorente-Herraiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Recio-Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Albi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"P\u00e9rez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M.","family":"Botella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6596-9600","authenticated-orcid":false,"given":"Angel M.","family":"Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"5825_CR1","doi-asserted-by":"publisher","unstructured":"Albi\u00f1ana V, Gallardo-Vara E, de Rojas PI, Recio-Poveda L, Aguado T, Canto-Cano A, Aguirre DT, Serra MM, Gonzalez-Peramato P, Martinez-Pineiro L, Cuesta AM, Botella LM (2020) Targeting beta2-adrenergic receptors shows therapeutical benefits in clear cell renal cell carcinoma from Von Hippel-Lindau disease. J Clin Med 9. https:\/\/doi.org\/10.3390\/jcm9092740","DOI":"10.3390\/jcm9092740"},{"key":"5825_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/jmedgenet-2017-104882","volume":"55","author":"L Aronoff","year":"2018","unstructured":"Aronoff L, Malkin D, Kv E, Gallinger B, Wasserman J, Kim RH, Villani A, Meyn MS, Druker H (2018) Evidence for genetic anticipation in vonHippel-Lindau syndrome. J Med Genet 55:395\u2013402. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104882","journal-title":"J Med Genet"},{"key":"5825_CR3","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1126\/science.286.5449.2528","volume":"286","author":"DW Bell","year":"1999","unstructured":"Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528\u20132531. https:\/\/doi.org\/10.1126\/science.286.5449.2528","journal-title":"Science"},{"key":"5825_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/jmedgenet-2016-104058","volume":"54","author":"ML Binderup","year":"2017","unstructured":"Binderup ML, Jensen AM, Budtz-Jorgensen E, Bisgaard ML (2017) Survival and causes of death in patients with von Hippel-Lindau disease. J Med Genet 54:11\u201318. https:\/\/doi.org\/10.1136\/jmedgenet-2016-104058","journal-title":"J Med Genet"},{"key":"5825_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E (2021) Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med 27:802\u2013805. https:\/\/doi.org\/10.1038\/s41591-021-01324-7","journal-title":"Nat Med"},{"key":"5825_CR6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1086\/426403","volume":"75","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131\u20131135. https:\/\/doi.org\/10.1086\/426403","journal-title":"Am J Hum Genet"},{"key":"5825_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13023-020-01410-y","volume":"15","author":"PI de Rojas","year":"2020","unstructured":"de Rojas PI, Albi\u00f1ana V, Recio-Poveda L, Rodriguez-Rufian A, Cuesta AM, Botella LM (2020) CLN5 in heterozygosis may protect against the development of tumors in a VHL patient. Orphanet J Rare Dis 15:132. https:\/\/doi.org\/10.1186\/s13023-020-01410-y","journal-title":"Orphanet J Rare Dis"},{"key":"5825_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamaneurol.2017.4469","volume":"75","author":"D Dornbos 3rd","year":"2018","unstructured":"Dornbos D 3rd, Kim HJ, Butman JA, Lonser RR (2018) Review of the neurological implications of von Hippel-Lindau disease. JAMA Neurol 75:620\u2013627. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4469","journal-title":"JAMA Neurol"},{"key":"5825_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/neuonc\/nov313","volume":"18","author":"A Feletti","year":"2016","unstructured":"Feletti A, Anglani M, Scarpa B, Schiavi F, Boaretto F, Zovato S, Taschin E, Gardi M, Zanoletti E, Piermarocchi S, Murgia A, Pavesi G, Opocher G (2016) Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro-Oncology 18:1011\u20131020. https:\/\/doi.org\/10.1093\/neuonc\/nov313","journal-title":"Neuro-Oncology"},{"key":"5825_CR10","doi-asserted-by":"publisher","first-page":"e0140819","DOI":"10.1371\/journal.pone.0140819","volume":"10","author":"O Havranek","year":"2015","unstructured":"Havranek O, Kleiblova P, Hojny J, Lhota F, Soucek P, Trneny M, Kleibl Z (2015) Association of germline CHEK2 gene variants with risk and prognosis of non-Hodgkin lymphoma. PLoS One 10:e0140819. https:\/\/doi.org\/10.1371\/journal.pone.0140819","journal-title":"PLoS One"},{"key":"5825_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3389\/fonc.2019.00490","volume":"9","author":"I Heidegger","year":"2019","unstructured":"Heidegger I, Pircher A, Pichler R (2019) Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front Oncol 9:490. https:\/\/doi.org\/10.3389\/fonc.2019.00490","journal-title":"Front Oncol"},{"key":"5825_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","volume":"176","author":"K Jaganathan","year":"2019","unstructured":"Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, Kosmicki JA, Arbelaez J, Cui W, Schwartz GB, Chow ED, Kanterakis E, Gao H, Kia A, Batzoglou S, Sanders SJ, Farh KK-H (2019) Predicting splicing from primary sequence with deep learning. Cell 176:535\u2013548.e524. https:\/\/doi.org\/10.1016\/j.cell.2018.12.015","journal-title":"Cell"},{"key":"5825_CR13","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1200\/JCO.2020.38.15_suppl.5003","volume":"38","author":"E Jonasch","year":"2020","unstructured":"Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Zojwalla NJ, Perini RF, Linehan WM, Srinivasan R (2020) Phase II study of the oral HIF-2\u03b1 inhibitor MK-6482 for Von Hippel-Lindau disease\u2013associated renal cell carcinoma. J Clin Oncol 38:5003\u20135003. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.5003","journal-title":"J Clin Oncol"},{"key":"5825_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317\u20131320. https:\/\/doi.org\/10.1126\/science.8493574","journal-title":"Science"},{"key":"5825_CR15","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S (2009) The sequence alignment\/map format and SAMtools. Bioinformatics 25:2078\u20132079. https:\/\/doi.org\/10.1093\/bioinformatics\/btp352","journal-title":"Bioinformatics"},{"key":"5825_CR16","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","volume":"361","author":"RR Lonser","year":"2003","unstructured":"Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) von Hippel-Lindau disease. Lancet 361:2059\u20132067. https:\/\/doi.org\/10.1016\/S0140-6736(03)13643-4","journal-title":"Lancet"},{"key":"5825_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3171\/2014.1.JNS131431","volume":"120","author":"RR Lonser","year":"2014","unstructured":"Lonser RR, Butman JA, Huntoon K, Asthagiri AR, Wu T, Bakhtian KD, Chew EY, Zhuang Z, Linehan WM, Oldfield EH (2014) Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg 120:1055\u20131062. https:\/\/doi.org\/10.3171\/2014.1.JNS131431","journal-title":"J Neurosurg"},{"key":"5825_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3171\/2008.4.17532","volume":"110","author":"RR Lonser","year":"2009","unstructured":"Lonser RR, Butman JA, Kiringoda R, Song D, Oldfield EH (2009) Pituitary stalk hemangioblastomas in von Hippel-Lindau disease. J Neurosurg 110:350\u2013353. https:\/\/doi.org\/10.3171\/2008.4.17532","journal-title":"J Neurosurg"},{"key":"5825_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41467-022-28084-3","volume":"13","author":"JA Martinez Fiesco","year":"2022","unstructured":"Martinez Fiesco JA, Durrant DE, Morrison DK, Zhang P (2022) Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding. Nat Commun 13:486. https:\/\/doi.org\/10.1038\/s41467-022-28084-3","journal-title":"Nat Commun"},{"key":"5825_CR20","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/0140-6736(91)91705-y","volume":"337","author":"HP Neumann","year":"1991","unstructured":"Neumann HP, Wiestler OD (1991) Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337:1052\u20131054. https:\/\/doi.org\/10.1016\/0140-6736(91)91705-y","journal-title":"Lancet"},{"key":"5825_CR21","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1371\/journal.pmed.0040060","volume":"4","author":"DM Park","year":"2007","unstructured":"Park DM, Zhuang Z, Chen L, Szerlip N, Maric I, Li J, Sohn T, Kim SH, Lubensky IA, Vortmeyer AO, Rodgers GP, Oldfield EH, Lonser RR (2007) von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med 4:e60. https:\/\/doi.org\/10.1371\/journal.pmed.0040060","journal-title":"PLoS Med"},{"key":"5825_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41586-021-03562-8","volume":"594","author":"AA Ren","year":"2021","unstructured":"Ren AA, Snellings DA, Su YS, Hong CC, Castro M, Tang AT, Detter MR, Hobson N, Girard R, Romanos S, Lightle R, Moore T, Shenkar R, Benavides C, Beaman MM, Muller-Fielitz H, Chen M, Mericko P, Yang J et al (2021) PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature 594:271\u2013276. https:\/\/doi.org\/10.1038\/s41586-021-03562-8","journal-title":"Nature"},{"issue":"872-884","key":"5825_CR23","doi-asserted-by":"publisher","first-page":"e875","DOI":"10.1016\/j.molcel.2019.09.004","volume":"76","author":"EM Terrell","year":"2019","unstructured":"Terrell EM, Durrant DE, Ritt DA, Sealover NE, Sheffels E, Spencer-Smith R, Esposito D, Zhou Y, Hancock JF, Kortum RL, Morrison DK (2019) Distinct binding preferences between Ras and Raf family members and the impact on oncogenic Ras signaling. Mol Cell 76(872-884):e875. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.004","journal-title":"Mol Cell"},{"key":"5825_CR24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1227\/01.neu.0000093497.81390.29","volume":"53","author":"V Van Velthoven","year":"2003","unstructured":"Van Velthoven V, Reinacher PC, Klisch J, Neumann HP, Glasker S (2003) Treatment of intramedullary hemangioblastomas, with special attention to von Hippel-Lindau disease. Neurosurgery 53:1306\u20131313; discussion 1313-1304. https:\/\/doi.org\/10.1227\/01.neu.0000093497.81390.29","journal-title":"Neurosurgery"},{"key":"5825_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ana.10807","volume":"55","author":"SD Wait","year":"2004","unstructured":"Wait SD, Vortmeyer AO, Lonser RR, Chang DT, Finn MA, Bhowmick DA, Pack SD, Oldfield EH, Zhuang Z (2004) Somatic mutations in VHL germline deletion kindred correlate with mild phenotype. Ann Neurol 55:236\u2013240. https:\/\/doi.org\/10.1002\/ana.10807","journal-title":"Ann Neurol"},{"key":"5825_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3171\/jns.2003.98.1.0082","volume":"98","author":"JE Wanebo","year":"2003","unstructured":"Wanebo JE, Lonser RR, Glenn GM, Oldfield EH (2003) The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 98:82\u201394. https:\/\/doi.org\/10.3171\/jns.2003.98.1.0082","journal-title":"J Neurosurg"},{"issue":"5","key":"5825_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1136\/jmg-2022-108633","volume":"60","author":"K Zhang","year":"2023","unstructured":"Zhang K, Yang W, Ma K et al (2023) Genotype-phenotype correlations and clinical outcomes of patients with von Hippel-Lindau disease with large deletions. J Med Genet 60(5):477\u2013483. https:\/\/doi.org\/10.1136\/jmg-2022-108633","journal-title":"J Med Genet"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-023-05825-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-023-05825-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-023-05825-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T14:18:49Z","timestamp":1703168329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-023-05825-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5825"],"URL":"https:\/\/doi.org\/10.1007\/s00701-023-05825-x","relation":{},"ISSN":["0942-0940"],"issn-type":[{"value":"0942-0940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Spanish National Research Council (CSIC) (references 075\/2017 and 228\/2020) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have read and agreed to the published version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}